Array BioPharma Inc. (ARRY)’s Insider Lunsen Van Sells 21,500 Shares of the Company; Last Week Enbridge Energy Partners, L.P. (EEP) Coverage

May 18, 2018 - By Sarah Hamilton

Array BioPharma Inc. (NASDAQ:ARRY) Logo

Enbridge Energy Partners, L.P. (NYSE:EEP) Ratings Coverage

Among 19 analysts covering Enbridge Energy Partners (NYSE:EEP), 6 have Buy rating, 2 Sell and 11 Hold. Therefore 32% are positive. Enbridge Energy Partners had 53 analyst reports since July 21, 2015 according to SRatingsIntel. On Monday, November 20 the stock rating was maintained by Barclays Capital with “Equal-Weight”. The stock of Enbridge Energy Partners, L.P. (NYSE:EEP) earned “Sell” rating by Goldman Sachs on Wednesday, July 20. The rating was upgraded by Credit Suisse on Monday, December 21 to “Outperform”. The stock of Enbridge Energy Partners, L.P. (NYSE:EEP) earned “Neutral” rating by Credit Suisse on Tuesday, November 3. Credit Suisse maintained Enbridge Energy Partners, L.P. (NYSE:EEP) rating on Tuesday, May 3. Credit Suisse has “Neutral” rating and $5 target. The stock has “Neutral” rating by Mizuho on Monday, January 30. The firm has “Hold” rating given on Wednesday, April 11 by Mizuho. The company was upgraded on Wednesday, September 7 by Simmons & Co. RBC Capital Markets maintained it with “Hold” rating and $2100 target in Sunday, August 13 report. The firm has “Neutral” rating by Credit Suisse given on Friday, April 7. See Enbridge Energy Partners, L.P. (NYSE:EEP) latest ratings:

17/04/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $16 New Target: $11 Maintain
11/04/2018 Broker: Mizuho Rating: Hold New Target: $12.0000 Maintain
28/03/2018 Broker: Citigroup Old Rating: Neutral New Rating: Neutral Old Target: $17 New Target: $10 Maintain
23/03/2018 Broker: Morgan Stanley Old Rating: Underweight New Rating: Underweight Old Target: $15 New Target: $11 Maintain
16/03/2018 Broker: Mizuho Rating: Hold New Target: $13.0 Maintain
16/03/2018 Broker: Ladenburg Thalmann Old Rating: Buy New Rating: Neutral Downgrade
13/03/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $16 New Target: $15 Maintain
02/03/2018 Broker: UBS Old Rating: Buy New Rating: Buy Old Target: $16.5 New Target: $14 Maintain
20/02/2018 Broker: Bank of America Old Rating: Underperform New Rating: Underperform Old Target: $14 New Target: $13 Maintain
11/01/2018 Broker: Morgan Stanley Rating: Sell Downgrade

Among 10 analysts covering Array BioPharma (NASDAQ:ARRY), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Array BioPharma has $23.0 highest and $7 lowest target. $18.14’s average target is 15.17% above currents $15.75 stock price. Array BioPharma had 38 analyst reports since June 3, 2016 according to SRatingsIntel. On Thursday, May 10 the stock rating was maintained by Cowen & Co with “Buy”. Stifel Nicolaus maintained Array BioPharma Inc. (NASDAQ:ARRY) rating on Tuesday, October 31. Stifel Nicolaus has “Buy” rating and $15.0 target. As per Sunday, September 10, the company rating was maintained by Cowen & Co. On Thursday, August 24 the stock rating was maintained by Jefferies with “Buy”. The rating was maintained by Cantor Fitzgerald on Tuesday, May 30 with “Buy”. The rating was maintained by Leerink Swann on Monday, September 26 with “Outperform”. The rating was maintained by Cowen & Co with “Buy” on Wednesday, February 7. As per Friday, February 3, the company rating was maintained by Stifel Nicolaus. On Monday, January 22 the stock rating was upgraded by Leerink Swann to “Outperform”. The stock of Array BioPharma Inc. (NASDAQ:ARRY) earned “Overweight” rating by Cantor Fitzgerald on Monday, September 11.

Analysts await Array BioPharma Inc. (NASDAQ:ARRY) to report earnings on August, 8. They expect $-0.25 earnings per share, down 47.06% or $0.08 from last year’s $-0.17 per share. After $-0.11 actual earnings per share reported by Array BioPharma Inc. for the previous quarter, Wall Street now forecasts 127.27% negative EPS growth.

Investors sentiment increased to 1.3 in Q4 2017. Its up 0.09, from 1.21 in 2017Q3. It improved, as 20 investors sold Array BioPharma Inc. shares while 50 reduced holdings. 27 funds opened positions while 64 raised stakes. 194.11 million shares or 1.73% more from 190.80 million shares in 2017Q3 were reported. 1.82 million were reported by Balyasny Asset Mngmt Limited Co. Putnam Limited invested 0.01% of its portfolio in Array BioPharma Inc. (NASDAQ:ARRY). Janney Montgomery Scott Lc holds 0% of its portfolio in Array BioPharma Inc. (NASDAQ:ARRY) for 23,650 shares. Landscape Management reported 0.09% stake. Sphera Funds Ltd has 0.61% invested in Array BioPharma Inc. (NASDAQ:ARRY). Franklin Res Inc reported 9.17M shares. 37,500 were reported by Badgley Phelps & Bell. Ameriprise holds 0% of its portfolio in Array BioPharma Inc. (NASDAQ:ARRY) for 192,142 shares. 2.81 million are owned by Millennium Mngmt Lc. Schwab Charles Inv invested 0.01% in Array BioPharma Inc. (NASDAQ:ARRY). Baxter Bros reported 0.05% stake. Swiss Bancorporation, a Switzerland-based fund reported 308,700 shares. Manufacturers Life Insur The holds 151,241 shares or 0% of its portfolio. Moreover, Amundi Pioneer Asset Mngmt has 0% invested in Array BioPharma Inc. (NASDAQ:ARRY). Hollencrest invested 0.24% in Array BioPharma Inc. (NASDAQ:ARRY).

Since December 16, 2017, it had 0 insider buys, and 9 insider sales for $16.27 million activity. On Saturday, December 16 the insider Robbins Andrew R sold $3.03 million. The insider VAN LUNSEN GIL J sold $360,340. Sandor Victor had sold 8,689 shares worth $133,376 on Sunday, April 1. 819,671 shares were sold by Squarer Ron, worth $8.90M. Another trade for 7,500 shares valued at $102,975 was made by Haddock Jason on Tuesday, January 16.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company has market cap of $3.27 billion. The companyÂ’s drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. It currently has negative earnings. The Company’s drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer.

More news for Array BioPharma Inc. (NASDAQ:ARRY) were recently published by: Profitconfidential.com, which released: “ARRY Stock Is Now Primed for a Move Toward Higher Prices” on May 14, 2018. Streetinsider.com‘s article titled: “Array Biopharma (ARRY) Announces Oral Presentation from the Pivotal Phase 3 COLUMBUS trial of the Combination ..” and published on May 16, 2018 is yet another important article.

Array Biopharma Inc’s director Lunsen Van sold 21,500 shares of the ‘s company in a transaction dated 17/05/2018. These transaction’s shares were sold at an average price per share of $15.4, for a total trade of $330,259. He also unloaded 21,500 shares worth total $326,585 USD in the last 30 days. Lunsen Van now indirectly owns 0 shares. He also directly owns 19297 shares. In total he holds a stake of 0.01%.

The stock increased 1.29% or $0.2 during the last trading session, reaching $15.75. About 1.48 million shares traded. Array BioPharma Inc. (NASDAQ:ARRY) has risen 68.58% since May 18, 2017 and is uptrending. It has outperformed by 57.03% the S&P500.

Enbridge Energy Partners, L.P. owns and operates crude oil and liquid petroleum transportation and storage assets; and natural gas assets in the United States. The company has market cap of $4.39 billion. It operates through two divisions, Liquids and Natural Gas. It has a 20.58 P/E ratio. The Liquids segment operates Lakehead system that consists of interstate common carrier crude oil and liquid petroleum pipeline, as well as storage assets, which transports crude oil and liquid petroleum from western Canada to the United States.

More news for Enbridge Energy Partners, L.P. (NYSE:EEP) were recently published by: Nasdaq.com, which released: “What’s Next For Oil?” on May 16, 2018. Fool.com‘s article titled: “Why Enbridge Energy Partners, LP Is Slumping Today” and published on May 02, 2018 is yet another important article.

Enbridge Energy Partners, L.P. (NYSE:EEP) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: